Aurora announces Q4 and full financial year 2017 results

Aurora Cannabis Inc.(TSX: ACB) (OTCQX: ACBFF) today announced its financial and operational results for the fourth quarter and full financial year ended June 30, 2017.

Q4 2017 Financial and Operational Highlights


Aurora starts to export medical cannabis to Germany

Aurora Cannabis (ACB.TO) (ACBFF) announced a major milestone this morning…

The Canadian licensed medical marijuana producer continues to execute and today, the company announced that it has received all the required permits to ship dried cannabis flower from Canada to Germany.

Aurora Cannabis will now be able to take advantage of a market that is experiencing a severe shortage of medical marijuana. Following this development, the company will start supplying the German medical cannabis market through its wholly-owned subsidiary Pedanios GmbH.

Ships 50 Kilograms of Medical Marijuana to Germany 


Volatility in cannabis land: will it affect prices for consumers?

The debate about the price of cannabis as well as its imminent “collapse” or price hikes has been around since there has been a legal market.

In general, the conventional wisdom is a bit off the mark. For the most part, even when it is accurate, it is highly regional and at best temporal, subject to uncertain if short-lived winds. Why? Every cannabis market these days is a different animal thanks to regulations. Further, the American state focussed industry is very different from any other country right now. Canada, Germany, Israel and Australia are more alike to each other than any similarities they share with the U.S. state industry. In any state.


Cannabis improves speech of tourette syndrome patients

In Patients With Tourette Syndrome

Hannover, Germany: The daily administration of cannabinoids is associated with improved speech fluency in patients with Tourette Syndrome (TS), according to a pair of case reports published in The International Journal of Molecular Sciences.

A pair of researchers from the Hannover Medical School in Germany assessed the impact of daily cannabinoid treatment in two TS patients with treatment-resistant vocal blocking tics. One patient underwent therapy utilizing THC-dominant whole-plant cannabis. The other utilized dronabinol (oral THC). 


MedReleaf Reports Q1 Fiscal 2018 Results

MedReleaf Corp. (TSX: LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced financial and operating results for the first quarter fiscal 2018 ending June 30, 2017. All amounts expressed are in Canadian dollars unless otherwise noted.


The Great Insurance Shuffle: A Schengen Border Dispute Or Something Wider?

It does appear that Europe is actually the place where insurance coverage is going to be defined properly for the first time.

While cannabis reform has certainly arrived, full force, in Europe, it is already a different discussion than anywhere else on the planet.

While the same elements are present in Europe as anywhere else (rec vs. medical, federal vs. regional reform), they are in a different form and focus than is happening in say the U.S. or Canada or Israel.

The most crucial point of this debate, however, right now, is how cannabis is or will be covered by health insurance. Now and into the future. In Europe right now, that has also created a strange standoff across a normally peaceful, open border.


Why Will Europe Be Slow in Legalising Medical Cannabis

Drug policy usually moves like an iceberg: slowly. And while and it can be hard to turn, sometimes it changes course in an unexpected direction. In the case of cannabis or marijuana, it may be picking up speed, but there are rough waters ahead.


Aurora Moves One Step Closer To Licensed Production In Germany

From Germany to Canada, Australia to Mexico, the benefits of marijuana are being recognized all over the globe and this trend is just getting started.

One of most significant developments so far this year the legalization of medical marijuana in Germany.

Expect 1+ Million Patients in Germany in the Coming Years

Germany is the largest country (by population) in the European Union and it represents a massive opportunity for marijuana companies. Per the most recent United Nations estimates, the current population of Germany is more than 80.6 million, which is twice the size of California.


Cannabis Makes Its Way Into the G-20 Summit

The G-20 summit is currently taking place in Hamburg, Germany and marijuana has made its presence known.

Although some of the expected discussion topics include climate change, security and trade, we think medical marijuana will be a topic that takes center stage. 20% of the countries at the G-20 summit have legalized medical marijuana and it will be a topic that is nearly impossible to ignore. Every country is looking for ways to lower its debt level and marijuana is the answer.

Marijuana will not only create a new revenue stream but it will also significantly decrease expenses and allow countries to better allocate its resources.

World Leaders Climb Aboard The Marijuana Train


Germany: The Global Cannabis Movement Continues

Germany is becoming a hotbed for Canadian cannabis producers and we think this trend is just getting started. 

Germany, the largest country in the European Union started 2017 by legalizing medical cannabis creating a major opportunity for cannabis businesses across the world. The legislation also will make cannabis available to people suffering from serious illnesses and available through health insurance plans.

These factors have led to a surge in the number of licensed Canadian medical cannabis producers focused on this market and we want to highlight some of the recent deals.

Aurora Makes Major Acquisition


Subscribe to RSS - Germany